The innate immune system is the body's first line of defense against pathogens and foreign substances. An essential component ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.